6C4S image
Deposition Date 2018-01-12
Release Date 2019-01-23
Last Version Date 2024-03-13
Entry Detail
PDB ID:
6C4S
Title:
Human cSrc SH3 Domain in complex with Choline Kinase fragment 60-69
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.50 Å
R-Value Free:
0.22
R-Value Work:
0.18
R-Value Observed:
0.18
Space Group:
P 1 21 1
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Proto-oncogene tyrosine-protein kinase Src,cSrc SH3 Domain
Gene (Uniprot):SRC
Chain IDs:A, B
Chain Length:74
Number of Molecules:2
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Molecular basis for the interaction between human choline kinase alpha and the SH3 domain of the c-Src tyrosine kinase.
Sci Rep 9 17121 17121 (2019)
PMID: 31745227 DOI: 10.1038/s41598-019-53447-0

Abstact

Choline kinase alpha is a 457-residue protein that catalyzes the reaction between ATP and choline to yield ADP and phosphocholine. This metabolic action has been well studied because of choline kinase's link to cancer malignancy and poor patient prognosis. As the myriad of x-ray crystal structures available for this enzyme show, chemotherapeutic drug design has centered on stopping the catalytic activity of choline kinase and reducing the downstream metabolites it produces. Furthermore, these crystal structures only reveal the catalytic domain of the protein, residues 80-457. However, recent studies provide evidence for a non-catalytic protein-binding role for choline kinase alpha. Here, we show that choline kinase alpha interacts with the SH3 domain of c-Src. Co-precipitation assays, surface plasmon resonance, and crystallographic analysis of a 1.5 Å structure demonstrate that this interaction is specific and is mediated by the poly-proline region found N-terminal to the catalytic domain of choline kinase. Taken together, these data offer strong evidence that choline kinase alpha has a heretofore underappreciated role in protein-protein interactions, which offers an exciting new way to approach drug development against this cancer-enhancing protein.

Legend

Protein

Chemical

Disease

Primary Citation of related structures